A Phase 2a, Multicenter, Randomized, Adaptive, Open-label, Dose Ranging Study to Evaluate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of Cobicistat-boosted GSK2838232 Monotherapy Over 10 Days in HIV-1 Infected Treatment-naive Adults

Trial Profile

A Phase 2a, Multicenter, Randomized, Adaptive, Open-label, Dose Ranging Study to Evaluate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of Cobicistat-boosted GSK2838232 Monotherapy Over 10 Days in HIV-1 Infected Treatment-naive Adults

Recruiting
Phase of Trial: Phase II

Latest Information Update: 25 May 2017

At a glance

  • Drugs Cobicistat (Primary) ; GSK 2838232 (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; Pharmacokinetics; Proof of concept
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 22 May 2017 Planned End Date changed from 19 Jun 2017 to 13 Nov 2017.
    • 22 May 2017 Planned primary completion date changed from 2 May 2017 to 13 Nov 2017.
    • 13 Apr 2017 Planned End Date changed from 2 May 2017 to 19 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top